Sickle cell disease remains a major public health challenge in India, particularly among tribal populations. According to ...

The upcoming ex-date tomorrow will be closely watched by investors, as it dictates eligibility for the final dividend, adding ...

Zydus Lifesciences has shown consistent growth in its financial performance, both on a quarterly and annual basis. The ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

India's Zydus Lifesciences has entered into a strategic deal to acquire select assets of Sterling Biotech, strengthening its ...

Zydus Therapeutics will file for the US Food and Drug Administration (FDA) approval of its late-stage primary biliary cholangitis (PBC) drug, saroglitazar magnesium. This follows the positive results ...

Shares of Sun Pharma fell 1.91% to Rs 1924. Market cap of the firm slipped to Rs 4.64 lakh crore. Lupin shares too slipped ...

Zydus Lifesciences and Apollo Hospitals partner to expand access to Shield Multi-Cancer Detection blood test in India, ...

US exports accounted for 46.16 per cent of Aurobindo Pharma's sales in FY26. For Sun Pharma, 30.26 per cent of its revenues ...

The agreement is part of Zydus’s exclusive arrangement with Guardant Health to introduce the Shield test in the Indian market.

India’s Zydus Lifesciences is in the FDA’s crosshairs once again, this time for a trio of unnamed violations at an injectables facility. Following an FDA inspection that wrapped up this week, Zydus, ...